Leadership Team

Marc Forth has served as our Chief Executive Officer since May 2019. Prior to AEON Biopharma, Mr. Forth was the Senior Vice President of Allergan PLC and Division Head for the U.S. Neurosciences, Urology and Medical Dermatology Division. During his 16 year tenure at Allergan, Mr. Forth was responsible for all aspects of the commercialization of both current and future products within Neurosciences, Urology and Medical Dermatology, most notably Botox® for all therapeutic uses. Prior to Allergan, Mr. Forth held various Sales and Marketing roles of increasing responsibility at TAP Pharmaceutical Inc., a specialty company focused on Urology, Oncology, Gynecology and Gastroenterology. Mr. Forth received a B.S. in Business Administration from California State University, Fresno and a Graduate Marketing Certification from Southern Methodist University.

Alex Wilson has served as our General Counsel & Corporate Secretary since August 2021. Prior to joining AEON Biopharma, Alex was the Associate General Counsel, Business Development & Sustainability of Glaukos Corporation. At Glaukos, he was responsible for a broad range of legal matters, including business development, capital markets, SEC reporting and ESG activities. Before Glaukos, Alex held the title of Counsel in the Newport Beach office of O’Melveny & Myers LLP where his practice focused on acquisitions, dispositions and capital markets transactions as well as corporate governance matters for a broad range of public and private company clients in a variety of industries, including healthcare, manufacturing and technology. Alex received a B.S. in Business Management from Brigham Young University and a J.D. from the UCLA School of Law.

Chad Oh, MD, our Chief Medical Officer, has more than 30 years of therapeutic clinical development experience in both industry and academia with a focus on CNS, infectious, respiratory, and autoimmune diseases, cancer and related rare diseases. He effectively facilitated the development of small molecules and biologics (including vaccines and botulinum toxin Type A) for therapeutic indications and led multiple submissions to U.S., European and Asian regulatory authorities to register these products for marketing. Prior to joining AEON, Dr. Oh held senior leadership roles in Clinical Development at Revance, Glenmark Pharmaceuticals and Medimmune/AstraZeneca and the Weinberg Group. Before joining the private sector, he spent 13 years at UCLA School of Medicine where he served as Associate Professor of Pediatrics and Head of the Allergy/Immunology and Rheumatology Clinics at Harbor-UCLA Medical Center. He has authored over 70 peer-reviewed publications and holds several patents. Dr. Oh received his M.D. from the Kyung-Hee University School of Medicine, Seoul, South Korea.